Chang-Yi Wang

Title: Chang-Yi Wang: Innovator in Hepatitis Diagnosis

Introduction

Chang-Yi Wang is a notable inventor based in Great Neck, NY (US). He has made significant contributions to the field of medical diagnostics, particularly in the area of hepatitis detection. His innovative work has led to the development of novel peptides that play a crucial role in diagnosing hepatitis infections.

Latest Patents

Chang-Yi Wang holds a patent for "Branched hybrid and cluster peptides effective in diagnosing and preventing non-A, non-B hepatitis (NANBH) and hepatitis C virus (HCV) infection." This invention focuses on branched synthetic substituted and hybrid peptides that contain specific epitopes. These peptides are effective in detecting NANBH-associated antibodies in patients using immunoassay techniques. Furthermore, the invention provides immunoassays for the detection and diagnosis of NANBH, as well as vaccine compositions for the prevention and treatment of NANBH or HCV infection.

Career Highlights

Throughout his career, Chang-Yi Wang has been associated with United Biomedical, Inc., where he has contributed to various research initiatives. His work has been instrumental in advancing the understanding and diagnosis of hepatitis infections.

Collaborations

Chang-Yi Wang has collaborated with Barbara Helen Hosein, further enhancing the research and development efforts in the field of hepatitis diagnostics.

Conclusion

Chang-Yi Wang's innovative contributions to hepatitis diagnosis through his patented peptides demonstrate his commitment to advancing medical science. His work continues to impact the field positively, providing new avenues for diagnosis and treatment.